EXECUTIVE INTERVIEWS

  • Navigating The Turbulent Waters From Discovery To Clinical
    Navigating The Turbulent Waters From Discovery To Clinical

    “A partnering deal with a bigger pharma company would certainly help us through [the Phase 3] process,” explains Jeff Davidson, CEO of Keystone Nano, a company that develops nanoparticles that target solid tumors by going after cancer cells and leaving the normal cells intact.

  • How To Survive The Perilous Life Sciences Startup Climb
    How To Survive The Perilous Life Sciences Startup Climb

    According to Noubar Afeyan, founder and CEO of Flagship Pioneering, his company shouldn’t be pigeonholed as a VC firm. ““From day one, our intent was to innovate and create new companies.” 

  • The Intriguing Origins Of A Gene Therapy Biopharma
    The Intriguing Origins Of A Gene Therapy Biopharma

    An inside look into how this fledgling biopharma has raised over $150 million and enlisted two high-profile CEOs from one of the hottest VC firms around, all in less than two years.

  • The Art Of Leadership
    The Art Of Leadership

    Former Pfizer exec and current partner at VC firm Polaris Partners Amy Schulman talks about what it takes to lead a pharma startup.

  • One Small Startup’s Quest For Funding Gets Creative
    One Small Startup’s Quest For Funding Gets Creative

    As CEO of Ensysce Biosciences, a semi-virtual company with three employees, Lynn Kirkpatrick, Ph.D., knows all about the funding struggles of a small company.

  • Breaking The Mold — A New Perspective On Alzheimer’s
    Breaking The Mold — A New Perspective On Alzheimer’s

    Casey Lynch has long had the gut feeling there was more to the cause of Alzheimer’s than beta amyloid and tau proteins. Turns out, she was right.

  • Industry Explorers Blaze On: Pat Andrews
    Industry Explorers Blaze On: Pat Andrews

    A look at the 26-year career of Pat Andrews, CEO of Boston Biomedical, who went from Big Pharma to small biotech.

  • Christi Shaw: Empathy Key To Transforming The Patient Experience
    Christi Shaw: Empathy Key To Transforming The Patient Experience

    The industry veteran talks about leaving Novartis to take care of her sister for a year and how that prepared her for her new job at Lilly.

  • Can Joseph Papa Save Valeant?
    Can Joseph Papa Save Valeant?

    When Joseph Papa took over Valeant Pharmaceuticals in May 2016, the company was in turmoil. We catch up with Papa and see how he’s coming with what he calls “the turnaround opportunity of a lifetime.”

  • A Celgene Exec's Unexpected Trip To Washington, D.C.
    A Celgene Exec's Unexpected Trip To Washington, D.C.

    Recounting what an executive did while on sabbatical wouldn’t normally fit into our editorial model. That is, unless that executive is Richard Bagger, J.D., EVP of corporate affairs and market access for Celgene.

  • Not a Bad Year, After All
    Not a Bad Year, After All

    Peter Meath, who heads the Life Science Group at J.P. Morgan’s Commercial Banking business, offers advice to novice entrepreneurs for turning a company’s novel science into a viable business.

  • 5 Leadership Questions For Camilla Harder Hartvig
    5 Leadership Questions For Camilla Harder Hartvig

    Camilla Harder Hartvig is SVP of Canada and EMEA for Alexion Pharmaceuticals. Previously she was president, Europe and emerging markets, at Glenmark Pharmaceuticals and also worked for companies such as Allergan, AstraZeneca, and Novartis in various managerial positions.

  • 2018: The Year Of Biosimilar Commercialization Wins Or Woes?
    2018: The Year Of Biosimilar Commercialization Wins Or Woes?

    We reached out to eight experts from biosimilar companies and consulting firms to see which topics they’ve been watching closely throughout 2017 and how they expect these trends will evolve and challenge the industry in 2018.

  • The Women Of Biopharma — Will They Gain Or Lose Ground In 2018?
    The Women Of Biopharma — Will They Gain Or Lose Ground In 2018?

    We hear from 11 women and one man in biopharma. Although we were not aiming for “balance” here — there are plenty of opposing opinions out there already — the sole gender-exception in this group supplies another valuable viewpoint…

More executive interviews

BEYOND THE PRINTED PAGE

More From Beyond The Printed Page

LIFE SCIENCE LEADER BLOGS

More From Life Science Leader Blogs

@LIFESCILEADER1